ARCT - Arcturus Therapeutics: Strategic opportunities beyond CSL
Arcturus Therapeutics is facing challenges with its collaboration with CSL regarding the KOSTAIVE Covid-19 vaccine, with CSL writing off $430 million related to the agreement and arbitration ongoing over milestone payments. This situation creates strategic opportunities for Arcturus to pivot towards new collaboration partners like Sanofi or BioNTech, who are looking to advance their mRNA vaccine pipelines. Despite current low investor confidence and declining revenue from the CSL agreement, Arcturus possesses valuable advanced RNA technology and a pipeline including rare disease programs, which could significantly increase its market capitalization through new partnerships.
Moderna (MRNA) Is Down 5.5% After FDA Sets Flu Vaccine Review, Tightens Lawsuit Venue Rules - What's Changed
Moderna's stock fell 5.5% after the FDA scheduled an advisory panel review for its mRNA-based seasonal flu vaccine and the company amended its bylaws to mandate federal court lawsuits for Securities Act claims. These developments, along with ongoing insider share sales and pediatric COVID-19 vaccine data, are increasing investor scrutiny on Moderna's regulatory pathway and legal risk management. The upcoming FDA review is particularly crucial as it follows a previous filing setback for the flu vaccine.
Keudell Morrison Wealth Management Invests $1.33 Million in Merck & Co., Inc. $MRK
Keudell Morrison Wealth Management recently invested $1.33 million in Merck & Co., Inc. (NYSE:MRK), purchasing 12,657 shares in the fourth quarter. The pharmaceutical giant has shown positive operating and pipeline updates, including beating earnings estimates and promising results from oncology trials. Despite some neutral and negative sentiments from analysts, Merck maintains a "Moderate Buy" rating with an average price target of $128.18.
Moderna’s once-rebuffed mRNA flu shot to face scrutiny from FDA adcomm
Moderna's mRNA flu vaccine, MFLUSIVA, will undergo scrutiny from the FDA's Vaccines and Related Biological Products Advisory Committee next month, after its application was initially refused earlier this year. The controversy stemmed from the FDA's assertion that Moderna's pivotal trial control group did not adequately reflect the best standard of care. Following a compromise, the amended application seeks regular approval for adults 50-64 and accelerated approval for those 65 and up, with a decision expected in August.
Total liabilities & shareholders' equities of Moderna, Inc. – BVL:MRNAUS
This page on TradingView provides financial information for Moderna, Inc. (MRNAUS) listed on the Lima Stock Exchange, specifically focusing on total liabilities and shareholders' equity. It indicates that the market is currently closed with no trades. The content highlights various data providers and TradingView's platform features, but no specific financial figures are presented in the provided text.
EBITDA per share of Moderna, Inc. – BVL:MRNAUS
This page provides financial information for Moderna, Inc. (MRNAUS) on the Lima Stock Exchange, specifically focusing on its EBITDA per share. It allows users to view the period, value, and change in EBITDA per share. The content is primarily a data placeholder within a financial platform.
FDA plans rare advisory hearing to debate Moderna’s flu shot
The FDA is planning a rare advisory hearing next month to review Moderna's experimental mRNA flu shot, signaling a potential increase in transparency after recent controversies. This follows the agency's initial refusal and subsequent reversal to review Moderna's application, which had surprised many. The hearing will allow external experts to provide recommendations, a practice that was less common during the previous administration.
Moderna, Merck cancer combo cuts melanoma spread risk at five years
A combination therapy by Moderna and Merck for skin cancer has shown a significant reduction in the risk of cancer spreading, according to mid-stage trial data. The therapy, which combines Moderna's personalized cancer vaccine intismeran autogene with Merck's Keytruda immunotherapy, reduced the risk of melanoma spreading by 59% after five years of follow-up. The results also indicated a 92.2% overall survival rate for the combination arm, compared to 71.3% for the Keytruda-alone group.
[144] Moderna, Inc. SEC Filing
This article provides details of a Moderna, Inc. (MRNA) SEC Form 144 filing from May 21, 2026. This form indicates a proposed sale of 9,263 shares of common stock with an aggregate market value of $433,879.85, acquired through options granted to the issuer. The filing also includes information about the company's market data, recent news, and other SEC filings.
Moderna's mRNA flu shot to face FDA panel in June
Moderna's mRNA-based influenza vaccine, mRNA-1010, is scheduled to be reviewed by an FDA advisory committee in June. This marks a significant step for the vaccine candidate as it moves closer to potential approval and commercialization. The FDA panel's decision will be crucial for Moderna's seasonal flu vaccine strategy.
Moderna Flu Shot Heads To FDA Advisory Panel
Moderna's experimental mRNA-based flu vaccine, mRNA-1010, is scheduled for review by an FDA advisory panel on June 18, with a decision expected by August 5. This public evaluation is noteworthy because such meetings have become less common, and it follows concerns from biotechnology companies, including Moderna, about regulatory hurdles and approval delays under the previous FDA Commissioner. The decision to hold a public meeting may signal a move towards greater transparency in the FDA's drug application evaluation process.
Shapiro Administration Highlights the Need for Funding to Grow Pennsylvania’s Innovation Economy During Visit to Thermo Fisher Scientific in Dauphin County
The Shapiro Administration is calling for increased funding to expand Pennsylvania's innovation economy, with Governor Josh Shapiro proposing nearly $100 million for the Innovate in PA 2.0 program in his 2026-27 state budget. This initiative aims to support key industries like life sciences, robotics, technology, energy, manufacturing, and agriculture, building on the state's historical leadership in discovery and innovation. During a visit to Thermo Fisher Scientific, DCED Secretary Rick Siger emphasized the importance of strategic investments to foster this vital ecosystem and attract industry leaders.
Asset turnover of Moderna, Inc. – BVL:MRNAUS
This article focuses on the asset turnover of Moderna, Inc. (BVL:MRNAUS) as listed on the Lima Stock Exchange. It provides financial context within the biotechnology sector, indicating the stock market for MRNAUS was closed at the time of the article. The content is primarily a placeholder for financial data on asset turnover.
Moderna, Inc. Cash Flow – BVL:MRNAUS
Moderna, Inc.'s Q1 2026 free cash flow was -2.42 billion PEN, following a -6.95 billion PEN free cash flow and -6.30 billion PEN operating cash flow for the full year 2025. The article provides a detailed look at Moderna's cash flow activities, including operating, investing, and financing, presented in both annual and quarterly formats. Financial data from 2016 through 2025 is available for various cash flow metrics.
Moderna (MRNA) Flu Vaccine Review Scheduled by FDA for June 2024
Moderna announced that its application for the flu vaccine, mRNA-1010, will be reviewed by the FDA's advisory committee on June 18, 2024. The FDA has set August 5, 2026, as the target decision date for approval for adults aged 50 and older, signaling a potential expansion of Moderna's product portfolio. Despite a strong growth potential (GF Score™ of 60/100), the company faces challenges in profitability and financial strength, and recent insider selling raises investor caution.
US FDA to hold expert committee meeting to review Moderna's flu vaccine
The U.S. FDA announced it will hold an expert committee meeting in June to review Moderna's experimental mRNA-based flu shot. The vaccine is currently under review after an initial rejection due to concerns about the comparison group's standard dose, but an amended application has been accepted with a decision expected by August 5. If approved, it would be the first mRNA seasonal flu shot in the U.S., despite prominent criticism of mRNA technology from figures like Robert F. Kennedy Jr.
Forget Moderna: This Biotech Juggernaut Is a Way Better Buy Right Now
Moderna's stock has surged significantly year-to-date, but the article argues that its fundamentals remain weak with projected revenue collapse and cash burn. In contrast, Gilead Sciences is presented as a superior long-term investment due to its strong free cash flow generation, growing HIV franchise with extended patent protection, and consistent shareholder returns through dividends and buybacks. The author concludes that Gilead offers more stable, retirement-portfolio-quality returns compared to Moderna's headline-driven bounce.
CytomX Therapeutics to Present at Upcoming June Investor Conferences
CytomX Therapeutics announced that its management will participate in two investor conferences in June: the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company, which focuses on developing conditionally activated biologics for cancer treatment, will provide a live webcast of its presentations and be available for one-on-one meetings with investors at both events.
BioNTech SE stock (US09075V1026): focus shifts from COVID boom to oncology pipeline and new data cat
BioNTech SE is transitioning its focus from its COVID-19 vaccine success back to its oncology pipeline, with recent governance changes and clinical updates highlighting this strategic shift. The company is deploying its COVID-19 related financial resources into expanding its clinical pipeline, manufacturing capabilities, and digital initiatives for individualized cancer vaccines. For U.S. investors, the stock's performance is increasingly influenced by trial readouts, regulatory milestones, and evolving revenue guidance from its oncology programs.
Did Adding Oncology Veterans to the Supervisory Board Just Shift BioNTech's (BNTX) Investment Narrative?
BioNTech recently expanded its Supervisory Board by adding two oncology and clinical development veterans, Prof. Iris Löw-Friedrich and Dr. Susanne Schaffert, at its Annual General Meeting. This move aims to strengthen the company's governance and support its oncology pipeline ambitions as it navigates shrinking COVID-19 revenues and ongoing losses. The investment narrative largely depends on the success of its oncology pipeline offsetting immediate financial challenges.
Moderna, Inc. Trade Ideas — LSX:A2N9D9
The article compiles various trade ideas and technical analyses for Moderna, Inc. (LSX:A2N9D9) from multiple traders. Discussions cover both bullish and bearish perspectives, analyzing price movements, RSI levels, potential breakouts, and corrections, often linking share performance to news like vaccine pricing and FDA designations.
Moderna’s stock rides hantavirus fears as spotlight returns to infectious disease platform
Moderna's stock saw a 20% surge due to emerging hantavirus cases, reminding investors of its pandemic defense capabilities, despite experts suggesting the virus poses a low global risk. While the company has early-stage hantavirus vaccine projects, its broader infectious disease pipeline has been reduced due to shifting U.S. government support and a focus on profitability. The hantavirus scare nonetheless provides an opportunity for Moderna to build goodwill and highlights the potential for changes in vaccine-related regulatory environments.
ROIV: Strong clinical progress and a $2.25B Moderna settlement drive robust financial position
Roivant Sciences (ROIV) has demonstrated strong clinical progress with IMVT-1402 and brepocitinib, the latter receiving FDA Breakthrough Therapy Designation. Furthermore, a substantial $2.25 billion settlement with Moderna has significantly bolstered the company's financial standing, bringing its cash and securities to $4.3 billion. This combination of clinical advancements and a strong financial position paints a robust outlook for ROIV.
Harvest Portfolios Group Inc. Has $63.10 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN
Harvest Portfolios Group Inc. reduced its stake in Regeneron Pharmaceuticals (REGN) by 24% in Q4, now holding 81,748 shares valued at approximately $63.1 million. Despite this reduction, Wall Street analysts maintain a "Moderate Buy" consensus for REGN with an average price target of $792.65. Regeneron Pharmaceuticals recently beat earnings expectations with $9.47 EPS and $3.61 billion in revenue, and declared a quarterly dividend of $0.94 per share.
Moderna Inc. stock (US60770K1034): FDA path, vaccine sales and pipeline updates in focus
Moderna Inc. (US60770K1034) shares are closely watched by U.S. investors due to developments in its mRNA pipeline, vaccine demand, and regulatory milestones. The company's stock is highly sensitive to trial results, FDA decisions, and commercial guidance, as it seeks to diversify revenue beyond COVID-19 products. Success in its respiratory, cancer, and rare disease programs will be key to transitioning from a single-product revenue model to a more stable growth story.
2 Healthcare Stocks Worth Investigating and 1 Facing Headwinds
This article analyzes three healthcare stocks, recommending two for investigation and one to potentially avoid. Moderna is highlighted as a stock to sell due to declining sales, profitability, and free cash flow margin. Conversely, Intuitive Surgical is presented as a strong watch due to robust revenue growth, share buybacks, and a healthy free cash flow margin, while BrightSpring Health Services is also recommended for its impressive revenue growth, large revenue base, and strong future growth estimates.
Moderna’s SWOT analysis: biotech stock faces profitability test
Moderna is at a crucial point, moving from its COVID-19 vaccine success to a more diverse pipeline of treatments and vaccines. The company is focusing on cost reduction and manufacturing expansion, which presents both opportunities and challenges for investors. Despite recent profitability challenges, new oncology treatments and an expanded manufacturing strategy could improve its financial outlook.
National HealthCare Corp stock hits all-time high at 199.7 USD
National HealthCare Corp's stock has reached an all-time high of $199.7 USD, reflecting an 88.62% increase over the past year and nearly 44% year-to-date gains. The company has also consistently raised its dividend for 12 consecutive years. Despite appearing overvalued by InvestingPro's analysis, the company continues strategic moves including a significant acquisition of 35 senior care facilities for $560 million, and shareholders recently re-elected key board members.
MRNA: International partnerships and new vaccines fuel growth amid strong clinical and regulatory progress
Moderna, Inc. (MRNA) is experiencing growth fueled by cost reductions, robust international partnerships, and new vaccine launches, particularly in oncology, supported by strong clinical data. The company is advancing regulatory approvals in the U.S. and Europe, and potential legal risks from intellectual property disputes are not expected to affect cash reserves. This assessment is based on an AI-generated summary of Moderna's RBC Capital Markets Global Healthcare Conference 2026 Audio Transcript.
OKYO Pharma Strengthens Scientific Advisory Board With Marta Sacchetti Appointment
OKYO Pharma has appointed Dr. Marta Sacchetti, MD, PhD, to its Scientific Advisory Board, enhancing the company's expertise in ophthalmic programs. Dr. Sacchetti brings extensive experience in neuro-inflammatory corneal diseases, aligning with OKYO Pharma's focus on unmet needs in ophthalmology. Her appointment is timely as OKYO Pharma advances its lead product candidate, Urcosimod, which has received IND and Fast Track designations for neuropathic corneal pain.
Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC
Lantern Pharma announced that the FDA raised no objections to their proposed amendments for the HARMONIC™ Phase 2 trial of LP-300. The amendments include focusing enrollment on never-smokers with EGFR exon 21 L858R mutations, extending LP-300 dosing to eight cycles, and transitioning to a single-arm study design. These changes aim to streamline the regulatory path and enhance the potential for LP-300 in a high-need patient population given its differentiated safety profile and emerging efficacy signals.
International Paper stock hits 52-week low at 29.45 USD
International Paper (IP) stock has fallen to a 52-week low of $29.45, reflecting a significant 40.61% decline over the past year. Despite this downturn, the company offers a 6.09% dividend yield and has maintained dividend payments for 56 consecutive years. Recent developments include stronger-than-expected Q1 2026 EPS, the acquisition of a facility in Delaware, and analyst upgrades to "Buy" due to improved operations and competitive position.
Bone Biologics extends rhNELL-1 protein shelf life to 29 months
Bone Biologics Corporation announced the validated shelf life of its rhNELL-1 protein product has been extended to 29 months, up from 24 months. This extension, supported by third-party stability data, is expected to provide greater flexibility for manufacturing and distribution ahead of a pivotal study. Despite recent stock struggles, the company is preparing for a clinical study of its lead product candidate, NB1, and has initiated an at-the-market offering to raise capital.
Profund Advisors LLC Increases Position in Amgen Inc. $AMGN
Profund Advisors LLC increased its stake in Amgen Inc. by 11% in the fourth quarter, bringing its total holdings to 62,287 shares valued at $20.4 million. This move follows Amgen's better-than-expected first-quarter results, with reported EPS of $5.15 and revenue of $8.62 billion, a 5.8% increase year-over-year. The company also announced a quarterly dividend of $2.52 per share, leading to an annualized yield of 3.1%, while analysts maintain a consensus "Hold" rating with an average price target of $356.15.
CRISPR Therapeutics stock (CH0334081137): gene-editing pioneer ahead of next earnings test
CRISPR Therapeutics, a gene-editing pioneer, is gearing up for its next earnings report with investors keenly watching its progress in gene-editing therapies and U.S. regulatory milestones. The company's business model relies heavily on collaborations and a robust pipeline focused on severe diseases like sickle cell, with future revenue potential tied to regulatory approvals and successful commercialization. Despite ongoing net losses due to significant R&D investment, the company's long-term value for U.S. investors lies in its ability to navigate complex regulatory landscapes and successfully bring its innovative CRISPR/Cas9-based treatments to market.
Moderna stock (US60770K1034): Insider sale adds to a volatile setup
Moderna President Stephen Hoge sold 53,336 shares on May 15 under a Rule 10b5-1 plan, contributing to the stock's volatile trading range. This insider sale provides a new data point for investors following the vaccine maker, whose shares are largely influenced by vaccine demand, pipeline execution, and market sentiment around mRNA technology. The company's future growth hinges on its ability to stabilize revenue post-pandemic and expand beyond its core respiratory vaccine franchise.
WVE-006 AATD trial shows strong biomarker gains for Wave Life Sciences (WVE)
Wave Life Sciences (WVE) announced positive updated data from its RestorAATion-2 Phase 1b/2a trial of WVE-006 for alpha-1 antitrypsin deficiency (AATD). The subcutaneous RNA editing therapy demonstrated significant reductions in harmful Z-AAT protein and restoration of protective M-AAT to levels observed in low-risk MZ individuals, alongside a favorable safety profile. The company anticipates FDA feedback on an accelerated approval pathway by mid-2026.
Moderna president Stephen Hoge sells $2.58m in shares
Moderna president Stephen Hoge sold 53,336 shares of the company's common stock for approximately $2.58 million on May 15, 2026, following the exercise of stock options for the same number of shares. This transaction was part of a Rule 10b5-1 trading plan adopted in November 2025. Despite the sale, Hoge retains significant direct and indirect holdings in Moderna, while the company focuses on vaccine research and regulatory compliance, with its stock showing a 97% gain over the past year.
Moderna (MRNA) president sells 53,336 shares after option exercises
Moderna President Stephen Hoge executed an exercise-and-sale transaction, acquiring 53,336 shares through stock options at $19.15 per share and subsequently selling them at an average price of $48.40 per share on May 15, 2026. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan established on November 13, 2025. Following these sales, Hoge's direct holdings in Moderna common stock amounted to 1,477,997 shares, with additional indirect holdings through a family trust and Valhalla, LLC.
Lorundrostat Phase 3 data in uncontrolled blood pressure, CKD going to ESH 2026
Mineralys Therapeutics (Nasdaq: MLYS) announced it will present new Phase 3 data from its Launch-HTN trial for lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026). The data, focusing on patients with uncontrolled hypertension and chronic kidney disease (CKD), will be presented orally on May 30, 2026, by Liffert Vogt, MD, PhD. The trial evaluated lorundrostat's efficacy and safety in adults whose blood pressure remained uncontrolled despite existing antihypertensive medications, with the primary endpoint being the change from baseline in systolic BP at six weeks.
BioVie Inc. Completes Final Patient Visit in SUNRISE-PD Phase 2 Trial for Bezisterim in Early-Stage Parkinson's Disease
BioVie Inc. has completed the final patient visit for its SUNRISE-PD Phase 2 trial of bezisterim for early-stage Parkinson's disease. The company expects to announce topline results in Q3 2026, which will inform the design of future Phase 3 trials. Bezisterim is an investigational oral drug targeting neuroinflammation and insulin resistance, with potential applications for Parkinson's, Long COVID, and Alzheimer's disease.
Pancreatic cancer RNAi trial moves ahead as Silexion ramps up spending
Silexion Therapeutics (NASDAQ: SLXN) reported its Q1 2026 financial results, highlighting progress on its SIL204 clinical trial for locally advanced pancreatic cancer, including regulatory approvals in Israel and Germany. While the company saw increased R&D spending and a wider net loss, it successfully raised capital post-quarter to meet Nasdaq's minimum shareholders' equity requirement. The Phase 2/3 trial for SIL204 is expected to commence in Q2 2026.
6M women get high-risk HPV yearly; new trial tests first potential drug
Daré Bioscience has initiated a Phase 2 clinical study for DARE-HPV, a novel pharmacologic treatment for persistent high-risk HPV infection, which currently has no FDA-approved therapies. This randomized, placebo-controlled trial will evaluate the safety and antiviral activity of DARE-HPV in approximately 100 women, with topline data expected in 2027. The program, backed by a $10 million ARPA-H contract, aims to intervene earlier in the infection process to prevent cervical cancer and address a significant unmet medical need affecting 6 million women annually in the U.S.
GeoVax moves higher before the bell as traders watch for Mpox vaccine news
GeoVax Labs Inc. shares saw a pre-market rally on Monday despite financial concerns and a lack of new clinical results following its Q1 update. The increase is attributed to anticipation of news regarding its GEO-MVA Phase 3 immunobridging study for mpox and smallpox. The company faces significant financial hurdles, with its cash balance expected to last only until June 2026, necessitating new capital.
Moderna Inc. stock (US60770K1034): Shares slip as post-COVID reset keeps volatility high
Moderna shares experienced a slip as the company navigates its transition from pandemic-driven COVID-19 vaccine sales to a broader portfolio of mRNA vaccines and therapeutics. This shift has resulted in continued stock volatility, with shares closing at $49.04, down 1.98%, reflecting investor uncertainty about the pace at which new products can offset declining COVID-19 revenues. The company's future stock performance will largely depend on its ability to convert its scientific pipeline and cash reserves into sustainable, recurring revenue streams beyond its initial pandemic success.
North Dakota State Investment Board Makes New $8.48 Million Investment in Salesforce Inc. $CRM
The North Dakota State Investment Board has acquired a new position in Salesforce Inc. (NYSE:CRM), purchasing 32,000 shares valued at approximately $8.48 million during the fourth quarter. This move comes as several other institutional investors have also modified their holdings in Salesforce, and the company recently reported strong quarterly earnings, exceeding analyst expectations. Salesforce has also initiated a quarterly dividend increase and authorized a significant $25 billion stock repurchase program, indicating confidence in its valuation.
Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Nanobiotix presented positive Part 1 data from the CONVERGE study at ESTRO 2026, evaluating JNJ-1900 (NBTXR3) in patients with stage 3 inoperable non-small cell lung cancer. The study showed promising interim efficacy results, including an 85.7% overall response rate and a 57.1% complete response rate in a subset of patients. JNJ-1900 (NBTXR3) is a novel nanotherapeutic designed to enhance radiotherapy, showing potential for scalability across solid tumors.
Japan Expands Approval Of GSK’s Arexvy To At-risk Adults Aged 18–49
Japan's Ministry of Health, Labour and Welfare has expanded the approval for GSK's RSV vaccine, Arexvy, to include adults aged 18 to 49 years who are at an increased risk for Respiratory Syncytial Virus disease. This decision also updates the prescribing information to explicitly include immunocompromised patients in the at-risk group. The expansion aims to protect a broader population, including those with chronic conditions, from severe RSV outcomes, supported by data demonstrating immune response and a consistent safety profile.
Evotec stock (DE0005664809): Key pipeline updates shape the 2026 setup
Evotec shares remain a focus for investors due to the company's pipeline execution, partner-funded research, and exposure to biotech funding conditions in Europe and the US. The German drug-discovery group's business model relies on early-stage drug discovery, preclinical services, and long-term partnerships, making collaboration announcements and pipeline progress key factors for sentiment. For US investors, Evotec offers exposure to the global biotech ecosystem and pharma R&D spending, but its shares are sensitive to shifts in biotech financing due to its service-oriented model.
Moderna Inc stock (US60770K1079): FDA review, vaccine pipeline and cash burn stay in focus
Moderna Inc. remains a key focus for investors due to its reliance on respiratory vaccines, pipeline development, and cash usage. The company's future stock performance is closely tied to regulatory decisions, new product adoption, and its ability to diversify revenue beyond its initial pandemic-era success. While offering substantial innovation in mRNA technology, Moderna's valuation is subject to significant volatility and headline-driven changes, presenting both opportunities and risks for US investors.
